Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational cohort study evaluating effectiveness and safety of tenofovir alafenamide based regimen in HIV infected patients

Next Previous
X
Search
Trial Profile

An observational cohort study evaluating effectiveness and safety of tenofovir alafenamide based regimen in HIV infected patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Emtricitabine/rilpivirine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir (Primary) ; Darunavir/ritonavir; Dolutegravir; Nevirapine; Raltegravir
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TAFNES

    • Most Recent Events

    • 08 Oct 2020 Results presented at the 15th International Congress on Drug Therapy and HIV Infection
    • 08 Oct 2020 Status changed from recruiting to completed, results presented at the 15th International Congress on Drug Therapy and HIV Infection
    • 08 Oct 2020 Results of M24 analysis of final 24-months presented at the 15th International Congress on Drug Therapy and HIV Infection

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top